{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-25-000037","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.491578+00:00","generated_at":"2026-05-21T05:19:33.566246+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gossamer Bio closes new patient screening in PAH Phase 3 PROSERA study; Q1 net loss $36.6M","bullets":["Enrollment of 343 patients completed; to exceed 350 by early June; topline results expected Feb 2026.","Baseline characteristics align with target: mean 6MWD 376 m, 74% Functional Class III, NT-proBNP 986 ng/L.","Phase 3 SERANATA study in PH-ILD to begin site activations in Q4 2025 with ~480 patients.","Cash $257.9M expected to fund operations into H1 2027; Q1 net loss $36.6M ($0.16/share).","Revenue from Chiesi collaboration $9.9M ($6.6M cost reimbursement); R&D expenses $38.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-25-000037","json":"https://secwatch.observer/filing/0001728117-25-000037.json","markdown":"https://secwatch.observer/filing/0001728117-25-000037.md","text":"https://secwatch.observer/filing/0001728117-25-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811725000037/0001728117-25-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811725000037/goss-20250515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T05:19:33.566246+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}